Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EuroXpand

Financiado

Cerrado

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cAr...

EUROpean clinical validation of a new ex vivo eXpanded stem cell theraPy for cArdiac regeNeration after acute myocarDial infarction EUROXPAND Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwid... ver más

31/12/2023

CELLPROTHERA

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

CELLPROTHERA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CELLPROTHERA

5.00M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

VASC-GEN Endoglin Mediated Vascular Regeneration to Promote Heart Rep... 231K€ Cerrado

EUIN2017-89173 CREACION DE MICROENTORNOS PARA LA REGENERACION CARDIACA IN V... 6K€ Cerrado

INC-TU-2011-1009 Estudio de viabilidad y eficacia de diferentes vías de inoc... Cerrado

CSC PHYSTRESS Bidirectional interactions between cardiomyocytes and cardia... 100K€ Cerrado

CARE-MI CARDIO REPAIR EUROPEAN MULTIDISCIPLINARY INITIATIVE 15M€ Cerrado

PTQ-09-02-00266 Regeneración de tejido cardiaco usando células madre cardiac... 83K€ Cerrado

Duración del proyecto: 68 meses Fecha Inicio: 2018-04-11
Fecha Fin: 2023-12-31

Líder del proyecto

CELLPROTHERA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years. With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue. Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development. In this context, CellProthera, founded in 2008, developed an innovative technology based on the discoveries of its founder, Pr. Hénon, who has worked on stem cells for more than 35 years. Unlike its competitors, CellProthera has already demonstrated the efficacy and the safety of its cell therapy, thanks to a successful Proof of Concept study. The clinical outcomes indicated an excellent safety profile associated with an outstanding long-term recovery of the cardiac function, facilitating socio-professional reinsertion. The process used during the pilot phase could not be patented nor industrialised, limiting its availability to all patients. Hence, Cellprothera has developed a patented cell expansion automate StemXpand®, combined with StemPack® Kit creating an innovative business model, and a new cell therapy process less invasive, more affordable, and decreasing health costs related to HF in the order of 50 to 75%. With the efficacy demonstration of the new process through EuroXpand project, Cellprothera’s cell therapy could become the reference treatment to prevent HF after AMI. This way, CellProthera will be in possession of all the assets required to achieve a leader position in HF prevention, after AMI. Indeed, with a potential of millions patients / year worldwide, Cellprothera’s total turnover is expected to reach 2,7 billion euros in 2030, associated to the creation of at least 70 direct jobs by 2027 and several thousands of indirect jobs, particularly in Cell Therapy Centres.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores